Document:

[Pursuant to 17 C.F.R. 240.24b-2, confidential
information has been omitted in places marked “[...***...]” and has been filed separately with the Securities
and Exchange Commission pursuant to a Confidential Treatment Application.]

 

RESEARCH AND DEVELOPMENT AGREEMENT

 

THIS RESEARCH AND DEVELOPMENT
AGREEMENT (this “Agreement”), dated as of March __, 2014 (the “Effective Date”), is made and entered into
by and between BioRestorative Therapies, Inc., a Nevada corporation (“BRT”), and Rohto Pharmaceutical Co., Ltd., a
Japanese corporation (“Rohto”) (collectively the “Parties” or individually a “Party”).

 

PRELIMINARY STATEMENTS

 

1.          BRT
has expertise in the field of stem cell biotechnology, and in particular with regard to [...***...].

 

2.          Rohto
is a well known pharmaceutical company in Japan which develops new technology at medical and cosmetic businesses and [...***...]
and seeks to use such materials for development of stem cell biotechnology.

 

3.          Rohto
desires to engage BRT to examine and research [...***...] owned by BRT, to develop [...***...] for use by Rohto
and to produce [...***...] BRT agrees to perform such services, subject to the terms and conditions hereof, and provide
to Rohto [...***...].

 

NOW, THEREFORE, in consideration of the
various promises and undertakings set forth herein, the Parties agree as follows:

 

ARTICLE I

 

OBJECTIVE AND ENGAGEMENT

 

1.01         Objective.
The objective of Rohto’s engagement of BRT in this Agreement is, subject to the terms and conditions hereof, to develop [...***...]
to be derived from [...***...] The Parties agree that the goal of this Agreement is, subject to the terms and conditions
hereof, to [...***...] derived from each of [...***...] provided by BRT or Rohto for such purposes.

 

1.02         Engagement.
Subject to the terms and conditions of this Agreement, Rohto agrees to engage BRT to conduct the Research Program (as defined hereinafter),
and BRT agrees to conduct the Research Program.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

ARTICLE II

 

RESEARCH PROGRAM

 

2.01         Rohto’s
Supply of Materials. Rohto shall provide to BRT [...***...] in amounts as reasonably necessary to conduct the Research
Program and as required by BRT from time to time. [...***...] will be provided [...***...] to BRT.

 

2.02         BRT’s Responsibility.
(a) BRT shall examine and research [...***...] (as defined in this Section 2.02) with the goal of [...***...]
obtained from each of [...***...] (for clarity, only [...***...] and only [...***...] is to be supplied
to Rohto) supplied by BRT using [...***...], and determining whether [...***...] It is understood that [...***...]
presently used by BRT [...***...] Thereupon, BRT shall seek to develop [...***...] for the above purpose [...***...],
if necessary, and develop a [...***...] (the “Research Program”). BRT shall provide [...***...]
during the Term (as hereinafter defined) [...***...] to Rohto. The Research Program is detailed in Exhibit A attached
hereto. BRT agrees that, except as otherwise provided for in this Agreement, it will [...***...] only for the Research
Program and not for any other purpose.

 

(b) With respect to
the shipping of biological material between BRT and Rohto, each Party that ships biological material will do so in accordance with
applicable international law and the respective laws of the jurisdictions from which and to which the materials are shipped. The
cost of shipping and insurance will be the responsibility of the shipper.

 

2.03         Rohto’s Responsibility.
Rohto shall pay BRT two hundred fifty thousand United States dollars (US $250,000) as the fee for the Research Program (the “Fee”).
The Fee will be paid by wire as follows:

 

(a)          one
hundred fifty thousand United States dollars (US $150,000) on the Effective Date;

 

(b) fifty thousand United States
dollars (US $50,000) within ten (10) days following the completion of Workstream 1 (as detailed in the Research Program) and the
commencement of Item 2 of Workstream 2 of the Research Program [...***...]; and

 

(c)          fifty
thousand United States dollars (US $50,000) (the “Final Installment”) within ten (10) days following Rohto’s
receipt of the final written report by BRT regarding the outcome of the Research Program (the “Final Report”).

 

2.04         Periodic Meetings.
The Parties agree to meet by telephone or other electronic means on a quarterly basis and for BRT to report in writing to Rohto
on the progress of the Research Program in a timely manner. The Parties will meet in such manner more frequently as needed. In
the event that BRT makes a discovery during the Research Program that it considers to be a breakthrough in research, it shall call
for a meeting with Rohto by telephone or other electronic means to discuss such findings immediately and after the meeting BRT
shall report the breakthrough and discussion between the Parties in writing in a timely manner. In the event the Parties determine
that the details of the Research Program are to be amended, the Parties will make such amendment in written form and attach it
to this Agreement as an amended Exhibit A and will modify the Fee to reflect any additional services to be provided by BRT. Any
travel expenses for any meetings in the United States with regard to the training of Rohto employees will be borne by Rohto; provided,
however, BRT shall obtain the prior written consent by Rohto for such expense.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

ARTICLE III

 

EXCHANGE OF INFORMATION, CONFIDENTIALITY,
AND OUTCOME 

 

3.01         Exchange of Information.
The Parties shall exchange all information as follows:

 

(a)         BRT shall disclose to Rohto
[...***...] to Rohto and will provide to Rohto [...***...] within thirty (30) days from the Effective Date.

 

(b)         Rohto
shall disclose to BRT [...***...] and will provide to BRT [...***...] within thirty (30) days from the Effective
Date.

 

3.02         Final Report. (a) The
Final Report shall include, without limitation, the following: [...***...] and other pertinent information in detail,
and [...***...].

 

(b)  BRT shall deliver the Final
Report to Rohto during the Term. If BRT determines that a certain extension of the Term is necessary in order to deliver the Final
Report, it shall make a request to Rohto for such extension of the Term at least thirty (30) days before the expiration of the
Term. Rohto shall respond to BRT’s request within seven (7) days of its receipt of BRT’s request. Rohto’s determination
with regard to an extension of the Term shall not be unreasonably withheld. In the event that Rohto agrees to such extension, BRT
may deliver the Final Report within such extended Term. If Rohto does not agree to such extension, BRT shall deliver the Final
Report within the Term.

 

3.03         Confidentiality. The
provisions of the Mutual Nondisclosure Agreement, of even date, attached hereto as Exhibit B, between the Parties (the “Nondisclosure
Agreement”) shall continue in full force and effect during the Term and for a period of [...***...] thereafter.

 

ARTICLE IV

 

TERM; TERMINATION

 

4.01         Term. This Agreement
shall commence as of the Effective Date and, unless sooner terminated or extended as provided hereunder, shall end one (1) year
from the Effective Date (the "Term"). The Term and the scope of this Agreement may be extended and expanded by mutual
written agreement.

 

4.02         Breach.
The failure by either Party to comply with any of the material obligations contained in this Agreement shall entitle the other
Party to give to the defaulting Party a default notice specifying the nature of the default and requiring it to cure such default.
If such default is not cured within thirty (30) days after the receipt of such notice (or, if such default cannot be cured
within such thirty (30) day period, or if the Party in default does not commence and diligently continue actions to cure such
default), the notifying Party shall be entitled to terminate this Agreement immediately by written notice. Rohto agrees that the
obligation to pay each installment of the Fee when due is a material obligation. Any termination by BRT of this Agreement as a
result of a breach by Rohto, as provided for above, shall not release Rohto of its obligations to pay the Final Installment, which
installment shall be due and payable upon such termination subject to the delivery of a report which reflects BRT’s progress
with regard to the Research Program until the date on which Rohto’s breach occurred.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

 

4.03        Surviving Rights. The
Parties' obligations under the Nondisclosure Agreement shall survive the expiration or termination of this Agreement.

 

ARTICLE V

 

INVENTIONS AND TECHNOLOGIES

 

5.01        Ownership of Outcome.
[...***...].

 

5.02        License.
(a) [...***...].

 

(b) [...***...].

 

ARTICLE VI

 

REPRESENTATIONS, WARRANTIES AND COVENANTS

 

6.01        Representations,
Warranties and Covenants. Each Party hereby represents and warrants to, and covenants with, the other Party as follows:

 

(a)         It is a company
or corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated,
and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business
as it is now being conducted and as contemplated in this Agreement.

 

(b)         As of the
Effective Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations
hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf
of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance
with its terms.

 

(c)         It
has not entered, and shall not enter, into any agreement with any third party that is in conflict with the rights granted to the
other Party under this Agreement, and has not taken and shall not take any action that would in any way prevent it from granting
the rights granted to the other Party under this Agreement, or that would otherwise materially conflict with or adversely affect
the rights granted to the other Party under this Agreement. Its performance and execution of this Agreement does not and will not
result in a breach of any other contract to which it is a party.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

ARTICLE VII

 

MISCELLANEOUS PROVISIONS

 

7.01         Relationship
of Parties. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, agency, employer-employee
or joint venture relationship between the Parties. Neither Party shall incur any debts or make any commitments for the other, except
to the extent, if at all, specifically provided herein.

 

7.02         Assignment. Except
as otherwise provided herein, neither this Agreement nor any interest hereunder shall be assignable by either Party without the
prior written consent of the other Party.

 

7.03         Publication. BRT may
not publish or otherwise publicly disclose (including, without limitation, in abstracts, presentations, meetings or seminars),
either in writing or orally, the results of studies on materials obtained from, or produced in collaboration with, Rohto unless
Rohto, in its sole discretion, agrees in writing to such publication and the content thereof. Rohto may publish or otherwise publicly
disclose (including, without limitation, in abstracts, presentations, meetings or seminars), either in writing or orally, the results
of studies on materials obtained from, or produced in collaboration with BRT, without any consent of BRT unless any BRT confidential,
proprietary or patentable information is included in the publication with BRT. If Rohto’s publication or disclosure includes
any BRT confidential, proprietary or patentable information, Rohto shall not publish or otherwise publicly disclose any such information
without the prior written consent of BRT. At least thirty (30) days prior to any such proposed publication or disclosure, Rohto
will provide to BRT a copy of the proposed document for publication or disclosure so that BRT may determine that no BRT confidential,
proprietary or patentable information is included.

 

7.04         Announcements.
Neither Party shall have the right to make any public announcement or other disclosure with respect to this Agreement, nor disclose
the terms of this Agreement, without the prior written consent of the other Party, except as follows:

 

(a)          each
Party may disclose the terms of this Agreement to the extent such disclosure is required by law (including without limitation by
the rules and regulations of the Securities and Exchange Commission, any securities exchange or NASDAQ) or to defend or prosecute
litigation or arbitration; provided, that, prior to such disclosure, to the extent permitted by law or such rules and regulations,
such disclosing Party notifies the other Party of such requirement and the disclosing Party furnishes only those terms of this
Agreement that the disclosing Party is legally required to furnish.

 

(b)          each
Party may disclose this Agreement to its (i) then-current and potential third party licensees and sublicensees, and (ii) then-current
and potential directors, investors, lenders and acquirers; provided, that such persons are bound to maintain the confidentiality
of this Agreement to the same extent as if they were parties hereto.

 

(c)          each
Party shall have the right to issue a press release in the form of Exhibit C attached hereto upon the signing of this Agreement.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

7.05         Arbitration. In the
event of any controversy or claim arising out of or relating to this Agreement, or the performance or breach thereof, which the
Parties cannot amicably resolve, the Parties agree to submit the matter for resolution under the Rules of Arbitration of the International
Chamber of Commerce to be decided by one or more arbitrators appointed in accordance with the said Rules. Said arbitration will
be held in New York, New York. The award of the arbitrator(s) shall be final and judgment upon such an award may be entered in
any competent court or application may be made to any competent court for juridical acceptance of such an award and order of enforcement.         

 

7.06         Sharing of Information.
BRT and Rohto shall keep each other currently informed of relevant progress, plans and information concerning the development,
manufacture, and use of cell lines, components and processes to the extent that they directly arise from the Research Program during
the Term.

 

7.07         No Trademark Rights.
Except as otherwise provided herein, no right, express or implied, is granted by this Agreement to use in any manner the name “BRT”
or “Rohto” or any other trade name or trademark of the other Party in connection with the performance of this Agreement.

 

7.08         Notices. All notices
and other communications hereunder shall be in writing, in English, and shall be deemed given if delivered personally or by facsimile
transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or
sent by an international express courier service of similar stature, to the Parties at the following addresses (or at such other
address for a Party as shall be specified by like notice; provided, that notices of a change or address shall be effective only
upon receipt thereof):

 

If to BRT addressed to:

 

555 Heritage Drive

Jupiter, Florida 33458

United States

Attention: Mark Weinreb, CEO

 

If to Rohto, addressed to:

 

Rohto Pharmaceutical Co., Ltd

1-8-1, Tatsumi-nishi, Ikuno-ku,

Osaka 544-8666, Japan

Attention: Tetsumasa Yamada

 

7.09         Amendment. No amendment,
modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by
a duly authorized officer of each Party.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

7.10         Waiver. No provision
of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument
in writing expressly waiving such provision and signed by the waiving Party.

 

7.11         Counterparts. This
Agreement may be executed simultaneously in two counterparts, either one of which need not contain the signature of more than one
Party but both such counterparts taken together shall constitute one and the same agreement.

 

7.12         Descriptive Headings.
The descriptive headings of this Agreement are for convenience only, and shall be of no force or effect in construing or interpreting
any of the provisions of this Agreement.

 

7.13         Governing Law. This
Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, applicable to contracts executed
and performed wholly within the State of New York.

 

7.14         Severability. Whenever
possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

7.15         Entire Agreement of the
Parties. This Agreement, together with the Nondisclosure Agreement, constitutes and contains the entire understanding and agreement
of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether
oral or written, between the Parties respecting the subject matter hereof.

 

7.16         Uncontrollable
Forces. Neither Party shall be considered to be in default of this Agreement if delays in or failure of performance shall be
due to uncontrollable forces the effect of which, by the exercise of reasonable diligence, such Party could not avoid. The term
“uncontrollable forces” shall mean any event which results in the prevention or delay of performance by BRT of its
obligations under this Agreement and which is beyond the control of such Party. It includes, but is not limited to, fire, flood,
earthquakes, storms, lightning, epidemic, war, riot, civil disturbance, sabotage, inability to procure permits, licenses, or authorizations
from any state, local, or federal agency or person for any of the supplies, materials, accesses, or services required to be provided
by either Rohto or BRT under this Agreement, strikes, work slowdowns or other labor disturbances, and judicial restraint.

 

7.17         Facsimile
or Email Signatures. Signatures hereon which are transmitted via facsimile or email shall be deemed original signatures

 

[Remainder of page intentionally left blank.
Signature page follows.]

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

IN WITNESS WHEREOF, each of the Parties
has caused this Agreement to be executed by its duly authorized officer as of the day and year first above written.

 

	 	BIORESTORATIVE THERAPIES, INC.
	 	 
	 	By:	 
	 	 	                   
	 	ROHTO PHARMACEUTICAL CO., LTD
	 	 
	 	By:	 

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

Exhibit A

 

Research Program

 

[...***...]

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

Exhibit B

 

Mutual Nondisclosure Agreement

 

MUTUAL NONDISCLOSURE AGREEMENT

 

AGREEMENT, made
this __ day of March, 2014, between BIORESTORATIVE THERAPIES, INC., a Nevada corporation, and ROHTO PHARMACEUTICAL CO.,
LTD., a Japanese corporation.

 

WHEREAS, the above
parties are engaged in discussions concerning a possible business transaction between them; and

 

WHEREAS, in order
to facilitate such discussions, certain Confidential Information (as hereinafter defined) may be disclosed between the parties.

 

NOW, THEREFORE,
it is agreed:

 

1.          Obligations.
This Agreement will confirm the understanding between the parties concerning the mutual obligations of confidentiality with respect
to Confidential Information furnished pursuant to this Agreement.

 

2.          Definition
of Confidential Information. As used in this Agreement, the term “Confidential Information” shall mean all communications,
documents and other information, whether in written, oral, printed, electronic, machine readable, or other form, which a disclosing
party furnishes to a receiving party with respect to itself and/or its subsidiaries and affiliates, regardless of the manner in
which it is furnished and shall include all information acquired by observation or otherwise during any site visit at a disclosing
party’s facility. “Confidential Information” shall include, but not be limited to, product plans, designs, market
research and analysis, costs, customer and supplier lists, strategies, forecasts, computer programs, technical data, know-how,
trade secrets, discoveries, inventions and any other intellectual property (whether or not patented), all other information disclosed
by one party to the other pursuant to this Agreement, and any and all analyses, compilations and other materials prepared by the
receiving party or any of its officers, directors, employees, representatives or agents (collectively, “Representatives”)
containing or based in whole or in part on any such information furnished by the disclosing party or its Representatives or otherwise
obtained by the receiving party or its Representatives.

 

3.          Confidentiality.
The parties acknowledge that each party considers the Confidential Information it discloses to be proprietary and confidential.
The Confidential Information will be kept confidential, will be used solely in connection with the evaluation of the proposed business
transaction and will not, without the prior written consent of the disclosing party, be used or disclosed, directly or indirectly,
in any manner whatsoever, in whole or in part. The receiving party agrees to exercise the same degree of care, but not less than
a reasonable degree of care, to preserve the confidentiality of the Confidential Information that it exercises with respect to
its own confidential information. Without limiting the generality of the foregoing, the receiving party shall not use any Confidential
Information for the purpose of effectuating a purchase or sale of the securities of the disclosing party. In addition, neither
party will disclose to any person or entity the fact that this Agreement has been entered into, that Confidential Information has
been provided under this Agreement, that discussions or negotiations are taking place or have taken place concerning a possible
transaction between the parties, or any of the terms, conditions or other facts with respect to any such discussions or possible
transaction, including the status thereof, except as required by law or regulation.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

4.           Disclosure
to Representatives. Each party agrees that a receiving party may disclose Confidential Information or portions thereof to those
of its Representatives who need to know such Confidential Information for the purpose of evaluating a possible transaction between
the parties. Prior to disclosing any Confidential Information to any Representative, the receiving party will inform such Representative
of the confidential nature of the Confidential Information. The receiving party agrees to be responsible for any breach of this
Agreement by its Representatives.

 

5.           Protective
Order. Notwithstanding any provision in this Agreement to the contrary, a receiving party may disclose Confidential Information
or portions thereof to the extent required to comply with an order issued by a court or governmental agency of competent jurisdiction;
provided, however, that, prior to disclosing any Confidential Information pursuant to an order of such court or governmental agency,
the receiving party shall give the disclosing party prompt notice so that it may seek, in its sole discretion, a protective order
or other appropriate remedy. In the event that such protective order or other remedy is not obtained, or the disclosing party waives
compliance with the provisions of this Agreement, only that portion of the Confidential Information which is legally required to
be disclosed will be furnished.

 

6.           Exceptions.
The obligations imposed upon the parties herein shall not apply to information:

 

		a.	which is publicly available prior to the date hereof;
or

 

		b.	which hereafter becomes available to the public through
no wrongful act of the receiving party; or

 

		c.	which was already in the possession of the receiving
party at the time of disclosure and not subject to an existing agreement of confidence between the parties; or

 

		d.	which is received from a third party without restriction,
not in violation of an agreement of confidence and without breach of this Agreement.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

7.          Ownership
of Confidential Information and Derivatives. All Confidential Information and any Derivatives (as hereinafter defined) thereof
remain the property of the party which created the Confidential Information and no license or other rights to Confidential Information
is granted or implied hereby. For purposes of this Agreement, “Derivatives” shall mean: (i) for copyrightable or copyrighted
material, any translation, abridgment, revision or other form in which an existing work may be recast, transformed or adapted;
(ii) for patentable or patented material, any improvement thereon; and (iii) for material which is protected by trade secret, any
new material derived from such existing trade secret material, including new material which may be protected by copyright, patent
and/or trade secret.

 

8.          No
Warranties or Representations as to Confidential Information. Each of the parties acknowledges that neither makes any express
or implied representation or warranty as to the accuracy or completeness of the Confidential Information, and neither party shall
have any liability to the other party or any of its Representatives relating to or arising from its or their use of any Confidential
Information or for any errors therein or omissions therefrom.

 

9.          Return
of Information. All Confidential Information furnished by one party to the other is considered loaned for use solely in connection
with the proposed business transaction, and shall be returned by the receiving party to the disclosing party upon request by the
disclosing party. The receiving party shall certify that it has destroyed or returned all copies of the Confidential Information
in its possession.

 

10.         Need
for Definitive Agreement. Each of the parties agrees that, unless and until a definitive written agreement between the parties
with respect to a business transaction has been executed and delivered, neither party will be under any obligation of any kind
whatsoever with respect thereto by virtue of this or any written or oral expression concerning such a transaction, except, in the
case of this Agreement, for the matters specifically agreed to herein.

 

11.         Equitable
Relief. Each party acknowledges and agrees that, in the event of any breach or threatened breach of any provision of this Agreement,
the disclosing party will be without an adequate remedy at law and, accordingly, shall be entitled to enforce such provisions by
temporary or permanent injunctive or mandatory relief obtained in an action or proceeding instituted in any court of competent
jurisdiction without the necessity of proving damages or posting any bond or other security and without prejudice to any other
rights or remedies which it may have at law or in equity.

 

12.         Applicable
Law. This Agreement shall be construed and interpreted in accordance with the laws of the State of New York, applicable to
agreements performed solely within the State of New York.

 

13.         Arbitration.
In the event of any controversy or claim arising out of or relating to this Agreement, or the performance or breach thereof, which
the parties cannot amicably resolve, the parties agree to submit the matter for resolution under the Rules of Arbitration of the
International Chamber of Commerce to be decided by one or more arbitrators appointed in accordance with the said Rules. Said arbitration
will be held in New York, New York. The award of the arbitrator(s) shall be final and judgment upon such an award may be entered
in any competent court or application may be made to any competent court for juridical acceptance of such an award and order of
enforcement.         

 

14.         Entire
Agreement. This Agreement sets forth the entire agreement and understanding of the parties with respect to the subject matter
hereof and supersedes all prior and contemporaneous agreements, arrangements and understandings relating thereto.

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

15.         Amendments;
Waivers. This Agreement may be amended only by a written instrument executed by each party or, in the case of a waiver, by
the disclosing party. The failure of the disclosing party at any time or times to require performance of any provision hereof shall
in no manner affect its right at a later time to enforce such provision or any other provision. No waiver by the disclosing party
of the breach of any term contained herein, whether by conduct or otherwise, in any one or more instances, shall be deemed to be
or construed as a further or continuing waiver of any such breach or the breach of any other term of this Agreement.

 

16.         Notices.
Any notices sent to the parties pursuant to the terms of this Agreement shall be hand delivered, transmitted by fax to the number
set forth on the signature page hereof or mailed by certified mail, return receipt requested, or overnight courier to the address
set forth on the signature page hereof, to the attention of the undersigned Representative of the party.

 

17.         Successors
and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the successors and assigns of the parties
hereto.

 

18.         Severability.
Any term or provision of this Agreement which is prohibited or held invalid or unenforceable in any jurisdiction shall, as to such
jurisdiction only, be ineffective only to the extent of such prohibition or unenforceability without invalidating the remaining
provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.

 

19.         Counterparts;
Facsimile and Email Signatures. This Agreement may be executed in separate counterparts, each of which counterparts shall be
deemed an original and all of which counterparts shall together constitute one and the same agreement. Facsimile and email signatures
shall be deemed to be original signatures.

 

20.         Communications.
Each party agrees that any and all communications by it or its Representatives regarding the provision of or access to Confidential
Information, and any and all discussions by it or its Representatives with respect to the proposed business transaction, shall
be conducted solely with the undersigned Representative of the other party, unless otherwise authorized by such person on behalf
of such other party.

 

21.         Representation
by Counsel; Interpretation. The parties acknowledge that they have been represented by counsel, or afforded the opportunity
to be represented by counsel, in connection with this Agreement. Accordingly, any rule or law or any legal decision that would
require the interpretation of any claimed ambiguities in this Agreement against the party that drafted it has no application and
is expressly waived by the parties. The provisions of this Agreement shall be interpreted in a reasonable manner to give effect
to the intent of the parties hereto.

 

{Remainder of page intentionally left
blank. Signature page follows.}

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

IN WITNESS WHEREOF,
the parties have executed this Agreement as of the date first above written.

 

	 	BIORESTORATIVE THERAPIES, INC.
	 	 
	 	By:	 
	 	 	Mark Weinreb
	 	 	Chief Executive Officer
	 	 
	 	555 Heritage Drive, Suite 130
	 	Jupiter, Florida 33458
	 	Fax Number: (561) 429-5684
	 	 
	 	ROHTO PHARMACEUTICAL CO., LTD.
	 	 
	 	By:	 
	 	 	Name: Tetsumasa Yamada
	 	 	Title: Head of Regenerative Medicine
	 	 	Research and Planning Division
	 	1-8-1, Tatsumi-nishi, Ikuno-ku,
	 	Osaka 544-8666, Japan
	 	Fax Number: (813)-6832-6024

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

Exhibit C

 

Press Release

 

[to be finalized by the Parties]

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.[Pursuant to 17 C.F.R. 240.24b-2, confidential
information has been omitted in places marked “[...***...]” and has been filed separately with the Securities
and Exchange Commission pursuant to a Confidential Treatment Application.] 

 

RESEARCH AGREEMENT

 

(“Agreement”)

 

Pfizer Inc, a Delaware corporation
with an address at 235 East 42nd Street, New York, New York 10017 (“PFIZER”), and BioRestorative
Therapies, Inc., a Nevada corporation with an address at 555 Heritage Drive, Jupiter, Florida 33458 (“BRT”),
enter into this Agreement for the conduct of studies entitled “Development and Validation of a Human Brown Adipose Cell
Model” as set forth in the research plan attached as Exhibit A (“Research Plan”).

 

		1.	DEFINITION:

 

		1.1.	“Affiliate” means any corporation, firm, partnership or other entity which directly
or indirectly controls, is controlled by, or is under common control with a particular party.

		1.2.	“Applicable Law” means any statute, law, treaty, rule, code, ordinance, regulation,
permit, interpretation, certificate or order of a Governmental Authority, or any judgment, decision, decree, injunction, writ,
order, subpoena, or like action of any court, arbitrator or other government entity related to the collection, retention, security
and use of the Material, as the same are promulgated and applied as of the effective date of this Agreement and at all times thereafter.

		1.3.	“BRT Material” means all materials or samples (including, without limitation,
[...***...]) provided by or on behalf of or otherwise made available by or on behalf of BRT to PFIZER pursuant to or
otherwise in connection with this Agreement.

		1.4.	“BRT Results” means and includes all technology, materials, intellectual property
and technical information that are developed by BRT employees, technicians or others working solely on behalf of BRT (excluding
any PFIZER employees or contractors) in performance of the Research Plan.

		1.5.	“Donor” means the donor of the Donor Material or of the original tissues from
which the Donor Material was derived.

		1.6.	“Donor Material” means cells, cell cultures, blood, fluids, tissues, genetic
information (including data or results derived from human brown and white adipose cell lines).

		1.7.	“Governmental Authority” means any federal, state, local or foreign government
entity, authority, agency, instrumentality, court, tribunal, regulatory commission or other body, whether legislative, judicial,
administrative or executive (or a combination or permutation thereof), and any arbitrator to whom a dispute has been presented
under government rule or by agreement of the parties with an interest in such dispute.

		1.8.	“HIPAA” means the Health Insurance Portability and Accountability Act of 1996,
as codified at 42 USC § 1320(d) and all regulations promulgated thereunder.

  

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

  

    	 

    	 

    

  

		1.9.	“Patient Identifiable Information” means any information (whether or not key
coded) that identifies, or could identify, the Donor and/or any individually identifiable, or potentially individually identifiable,
health information of that Donor, including, without limitation, Protected Health Information (as defined in 45 CFR § 164.501)
or Individually Identifiable Health Information (as defined in 42 USC § 1320(d)) and other information protected by data protection
and/or privacy legislation in any and all applicable territories.

		1.10.	"PFIZER Material" means all materials or samples (including, without limitation,
[...***...]) provided by or on behalf of or otherwise made available by or on behalf of PFIZER to BRT pursuant to or
otherwise in connection with this Agreement.

		1.11.	“PFIZER Results” means and includes all technology, materials, intellectual
property and technical information that are developed by PFIZER employees, technicians or others working solely on behalf of PFIZER
(excluding any BRT employees or contractors) in performance of the Research Plan.

		1.12.	“Privacy Board” means a review body that is established to act upon requests
for a waiver or an alteration of the authorization requirement under the privacy rule for uses and disclosures of Patient Identifiable
Information for the relevant research study.

 

		2.	SCOPE OF WORK: BRT, under the direction of principal investigator, Francisco Silva, Vice
President, Research & Development (“Principal Investigator”), will perform the studies and provide to PFIZER
the data and reports described in the Research Plan.

 

		3.	TERM: The term of this Agreement is effective
as of March 24th, 2014 (“Effective Date”) and unless earlier terminated or extended,
continues for two (2) years until March 23rd ,2016 (the “Expiration Date”), or until the
completion of the work described in the Research Plan, whichever comes first.

 

		4.	PAYMENT: PFIZER will pay BRT up to the sum of $775,000 (Seven Hundred and Seventy
Five Thousand Dollars) during the term of this Agreement according to the following payment schedule:

 

		·	The sum of $250,000 (Two Hundred
Fifty Thousand Dollars) (the “Initial Payment”) – which represents technology access fee, upfront costs,
and Q1 labor costs associated with Workstream #1 — will be payable concurrently with the execution of this Agreement.

		·	The sum of $356,250 (Three Hundred
Fifty-Six Thousand Two Hundred Fifty Dollars) (the “Second Installment”) will be payable in four (4) equal quarterly
installments (of $89,062.50 for Q2, Q3, Q4, and Q5) commencing on the three (3) month anniversary of the Effective Date and continuing
every three (3) months thereafter (each, a “Quarterly Period”); provided, however, that, in the event of the
achievement of Workstream #1 Deliverable #1 — Delivery from BRT to PFE of [...***...], the
balance of the Second Installment shall be due and payable.

		·	The
                                         sum of $168,750 (One Hundred Sixty-Eight Thousand Seven Hundred Fifty Dollars)
                                         (the “Third Installment”) will be payable in two (2) equal bi-annual
                                         installments (of $84,375) following the Second Installment and continuing every six (6)
                                         months thereafter (each, a “Bi-Annual Period”); provided, however,
                                         that, in the event of achievement of Workstream #2 Deliverable #2 — analysis
                                         of [...***...] and delivery of the final report to
                                         PFIZER, the balance of the Third Installment
                                         shall be due and payable.

  

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

 

    	 

    	 

    

  

			Payments under this Agreement will be due within thirty (30) days following PFIZER’s receipt
of an invoice from BRT (except that the Initial Payment shall be paid concurrently with the execution of this Agreement).

 

All invoices shall be delivered
to PFIZER c/o: PFIZER INC. GFSS – AMERICAS, PO Box 34600, Bartlett, TN 38184-0600, United States. To receive payment from
your purchase order (PO), mail a document clearly marked 'INVOICE' to the address above (or email apinvoices@pfizer.com)
with the following information clearly listed: Description of research conducted, and/or goods provided, PO number, amount owed
and name and address payment is to be sent to. This will help facilitate a quick payment to BRT for research conducted. BRTs enrolled
in PFIZER's e-Invoicing programs (ASN or OB10) can ignore this PO Note. All invoice or billing related questions should be referred
to PFIZER's Accounting Department at 800.601.1357 or go to the Accounts Payable Inquiry Tool (APIQ) at www.pfizeraccountspayable.com.

 

In addition, a copy of each invoice
will be mailed and emailed to:

 

Michael Rukstalis, Principal Scientist

 

CVMED Research Unit

 

Pfizer Worldwide Research &
Development

 

Cambridge Laboratories

 

610 Main St

 

Cambridge, MA 02139

 

with an electronic copy to:

 

Michael Rukstalis at: michael.rukstalis@pfizer.com

  

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

  

    	 

    	 

    

  

		5.	PFIZER & BRT MATERIAL:

		5.1.1.	Ownership, Delivery and Handling. BRT acknowledges and agrees that, as between the parties,
PFIZER is and shall at all times remain the sole and exclusive owner of the PFIZER Material and all intellectual property rights
therein. PFIZER acknowledges and agrees that, as between the parties, BRT is and shall at all times remain the sole and exclusive
owner of the BRT Material and all intellectual property rights therein. PFIZER will supply BRT with such quantities and types of
the PFIZER Material as PFIZER in its sole discretion determines is appropriate under the Research Plan, and BRT will supply PFIZER
with such quantities and types of the BRT Material as BRT in its sole discretion determines is appropriate under the Research Plan.
Upon the sooner of the expiration or termination of this Agreement or upon the request of PFIZER, BRT shall, in accordance with
PFIZER’s instructions, return to PFIZER, or destroy at PFIZER’s option with written certification of such destruction
sent to PFIZER, all unused PFIZER Material. Upon the sooner of the expiration or termination of this Agreement or upon the request
of BRT, PFIZER shall, in accordance with BRT’ instructions, destroy with written certification of such destruction sent to
BRT, all stem cell lines in PFIZER’s possession that were developed by BRT during the performance of the Research Plan and
were not selected by PFIZER pursuant to the Workstream 1 Deliverables set forth in the Research Plan for further analysis in Workstream
2.

 

		5.1.2.	Experimental Materials. BRT acknowledges that the PFIZER Material comprises experimental
materials and BRT will comply with all laws and regulations applicable to handling and use of such materials. BRT will not use
the PFIZER Material for testing in or treatment of human subjects. PFIZER acknowledges that the BRT Material comprises experimental
materials and PFIZER will comply with all laws and regulations applicable to handling and use of such materials. PFIZER will not
use the BRT Material for testing in or treatment of human subjects.

 

		5.1.3.	NO WARRANTY. THE PFIZER MATERIAL AND BRT MATERIAL ARE PROVIDED TO THE OTHER PARTY AS-IS
AND WITHOUT WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, TITLE, OR FITNESS FOR A PARTICULAR
PURPOSE.

 

		5.1.4.	Transfer of Material. BRT will not transfer, disclose, make available, or sell any of the
PFIZER Material to any third party. BRT shall not modify or use the PFIZER Material other than as expressly permitted under the
Research Plan. PFIZER will not transfer, disclose, make available, or sell any of the BRT Material to any third party except
as permitted under Section 6(a).

 

		5.1.5.	Use of Material. BRT will use the PFIZER Material solely for the purpose of performing the
Research Plan. BRT shall not analyze the PFIZER Material or attempt in any way to discover the identity, structure, mechanism of
action, or composition of the PFIZER Material other than as expressly permitted under the Research Plan. Notwithstanding any provision
in this Agreement to the contrary, PFIZER shall not be obligated at any time to disclose to BRT the identity, structure, composition
of, or other information concerning, the PFIZER Material.

 

		6.	INTELLECTUAL PROPERTY:

 

(a) BRT Materials; BRT Results.
[...***...] 

 

(b)          PFIZER Related IP.
[...***...]

  

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

  

    	 

    	 

    

  

(c)  PFIZER Materials; PFIZER
Results. [...***...]

 

(d)  [...***...]

 

		7.	INFORMATION: For purposes of this Agreement, the term “Information” means
all written information relating to the studies described in the Research Plan, including but not limited to data, know-how, materials,
compound samples and compound specifications which PFIZER shall deliver to BRT, or BRT shall deliver to PFIZER, pursuant to this
Agreement, stamped “Confidential,” or disclosed to BRT or PFIZER, as the case may be, orally declaring same to be confidential
and confirming such declaration in writing within thirty (30) days of disclosure.

 

		8.	CONFIDENTIALITY: Each party agrees to maintain the Information in confidence with the same
degree of care it holds its own confidential information. Neither party will use the Information except for the studies described
in the Research Plan or as otherwise permitted herein to practice the rights granted herein. Each party will disclose the Information
only to its officers, directors, employees and consultants directly concerned with the studies, but will neither disclose information
to any third party nor use the Information for any other purpose.

 

		9.	EXCEPTIONS TO CONFIDENTIALITY: Each party’s obligation of nondisclosure and the limitations
upon the right to use the Information shall not apply to the extent that such party can demonstrate that the Information: (a) was
in the possession of such party prior to the time of disclosure; or (b) is or becomes public knowledge through no fault or omission
of such party; or (c) is obtained by such party from a third party under no obligation of confidentiality to the other party.

 

			In the event a party is legally required to disclose any of the Information, such party shall provide
prompt prior written notice of such requirement to the other party, afford the other party an opportunity to secure confidential
treatment for such disclosure, and if the other party is unsuccessful, furnish only that portion of the Information which such
party is legally required to disclose.

 

		10.	SURVIVAL OF CONFIDENTIALITY OBLIGATIONS: All obligations relating to confidentiality of
the parties under this Agreement shall survive the termination of this Agreement for a period of [...***...].

 

		11.	DONOR MATERIAL: BRT represents that the Donor Material used in, provided to PFIZER, pursuant
to this Agreement will conform to the overall description, features, function and specifications set forth in the Research Plan.
Furthermore, BRT represents and warrants the following:

11.1.            BRT
will not provide to PFIZER any medical information or Patient Identifiable Information about any Donor.

11.2.            BRT
will comply with all Applicable Laws and obtain all required governmental permits, licenses and authorizations in the collection
and handling of the Donor Material.

11.3.            Collection
of the Donor Material has been approved by an Institutional Review Board (“IRB”) that complies with all Applicable
Laws for such a body.

11.4.            An
IRB-approved informed consent form (“ICF”) compliant with all Applicable Laws, will be signed by and obtained from
each Donor (or Donor’s representative in the event that the Donor is incapacitated) prior to donation in respect of each
Donor Material (or the tissue from which the Material was derived) (“Informed Consent”).

  

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

  

    	 

    	 

    

  

11.5.            BRT
has legal right and title to the Donor Material and has the required Donor consent to transfer the Donor Material to PFIZER.

11.6.            Uses
of the Donor Material described in the Research Plan are within the scope of and consistent with BRT’s ethical approval policies,
if any, the Informed Consent, and the IRB’s approval.

 

		12.	REPORTS: BRT shall cause the Principal Investigator to furnish to PFIZER a comprehensive
report within thirty (30) days of the one year anniversary of the Effective Date, describing in reasonable detail the work accomplished
on the studies described in the Research Plan.

 

		13.	DISCLOSURE OF FEES: As part of any disclosure policy that may be implemented from
time-to-time by a party regarding payments made to members of the medical or scientific community, or in accordance with applicable
laws or regulations, such party shall have the right to disclose any terms related to this Agreement, including the Principal Investigator’s
name and the fees provided to BRT hereunder.

 

		14.	HANDLING OF PATIENT INFORMATION:

14.1.             BRT
and PFIZER will each comply in all material respects with all Applicable Law regarding the privacy of Patient Identifiable Information
(including during collection, use, storage, and disclosure), including, but not limited to, HIPAA and any current and future regulations
promulgated thereunder including without limitation the federal privacy regulations contained in 45 CFR Parts 160 and 164, the
federal security standards contained in 45 CFR Parts 106 and 162, all collectively referred to herein as “HIPAA Requirements”).

14.2.             BRT
agrees to collect, use, store, and disclose Patient Identifiable Information collected or provided as part of the Research Plan
and for the purpose of complying with applicable law, provided that all such uses are disclosed in the ICF.

14.3.             BRT
will ensure that that ICF provides PFIZER may use the Donor Material for any research, development and regulatory purpose.

14.4.             BRT
agrees that it will not disclose to PFIZER any Patient Identifiable Information of any Donor and PFIZER will not attempt to identify
any Donor.

14.5.             If
PFIZER inadvertently receives Patient Identifiable Information from BRT, PFIZER will take appropriate measures to protect the privacy
and confidentiality of such information and to ensure that PFIZER’s collaborators take similar measures.

 

		15.	ENTIRE AGREEMENT: This Agreement sets forth the entire agreement between PFIZER and BRT
as to its subject matter. None of the terms of this Agreement shall be amended except in writing signed by both parties.

 

		16.	BREACH AND TERMINATION: If either party breaches this Agreement in any material respect,
the other party may terminate it if the breaching party does not cure the breach within thirty (30) days of written notice of the
same (a “Breach Termination”). PFIZER may terminate this Agreement [...***...] by giving thirty (30)
days notice to BRT in writing. [...***...] The right of termination shall be an addition to any other rights the terminating
party may have, at law or equity, pursuant to this Agreement. Sections 1, 5, 6, 8, 9, 10, 15 and 18 shall survive any termination
of this Agreement, whether due to a breach or otherwise.

  

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

  

    	 

    	 

    

  

		17.	COMPLIANCE WITH LAWS: Both PFIZER and BRT shall comply in all material respects with the
requirements of all Applicable Laws, rules, regulations and orders of any government authority including laws related to animal
welfare. BRT will comply with Pfizer’s animal care and use policy — http://www.pfizer.com/research/research_clinical_trials/laboratory_animal_care
.. BRT will procure all Donor Material in accordance with all Applicable Laws. Additionally, PFIZER agrees to use the Donor Material
in compliance with all Applicable Laws. BRT shall not use services of any BRT employees that have been or are currently debarred
or otherwise disqualified by the United States Food and Drug Administration or other regulatory or certification authority.

 

17.1.             Regulatory.
BRT is solely responsible for any and all safety reporting and regulatory obligations associated with the procurement of the Donor
Material.

17.2.             Standards.
BRT will procure the Donor Material in accordance with International Conference on Harmonization Good Clinical Practice (“ICH
GCP”) guidelines (to the extent applicable), and all Applicable Laws. BRT will comply with all IRB requirements relating
to the procurement of Donor Materials.

17.3.             IRB
Approval. If required, BRT will ensure that the procurement of the Donor Material is approved by and subject to continuing
oversight by an appropriate IRB.

17.4.             Informed
Consent. As required, BRT will obtain Informed Consent from each Donor in accordance with Applicable Law (including without
limitation 21 Code of Federal Regulations Part 50), ensure that Informed Consent that covers the research to be conducted has already
been obtained, or obtain a waiver of Informed Consent for procurement of the Donor Material from an appropriate IRB. If an Informed
Consent is used, BRT will inform Donors that Pfizer is providing support for procurement of the Donor Material. Pfizer has no obligation
to participate in the development of, or to review or comment on, an ICF, authorization, or waiver request.

 

		18.	CHOICE OF LAW: This Agreement shall be construed in accordance with the laws of the State
of New York, excluding choice of law principles thereof.

 

[Remainder of page intentionally left blank.
Signature page follows.]

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

IN WITNESS WHEREOF, duly-authorized
representatives of the parties have signed as of the dates written below.

 

	BioRestorative Therapies, Inc.	 	 	Pfizer Inc.	 

 

 

	By:	 	 	By:	 

 

 

	Print Name:	 	 	Print Name:	 

 

 

	Title:	 	 	Title:	 
	 	 	 	 	 
	 	(Duly authorized)	 	 	(Duly authorized)

 

[...***...] Confidential information
has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to this omitted information.

 

    	 

    	 

    

  

EXHIBIT A

 

RESEARCH PLAN

 

[...***...]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]